Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | SI | P14410 | 1/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212003 | 0.84 | GAA (0.58) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10575074 | 0.84 | MGAM (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL113191 | 0.83 | GAA (0.56) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL8627208 | 0.81 | TSHR (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL29185376 | 0.79 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL182126 | 0.79 | GAA (0.64) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28519835 | 0.79 | GAA (0.64) | GAAMGAMSIMGAM2ALDH1A1 | |
| Malonic Acid Diethyl Ester SCHEMBL28023329 | 0.79 | GAA (0.71) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4418314 | 0.77 | GAA (0.61) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18890 | 0.77 | GAA (0.61) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56034664-A | — | — | None | — | — | JP | disclosed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| EP-4313300-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117460723-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| EP-0024464-B1 | 2-OXOPROPIONALDEHYDE BIS(THIOSEMICARBAZONE)DERIVATIVES AND THEIR PRODUCTION AND USE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
| US-4287362-A | AS CHELATING AGENTS IN COMBINATION WITH PROTEINS AND A RADIOACTIVE ISOTOPE OF TECHNETIUM FOR DIAGNOSIS | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1981-09-01 | — | — | US | disclosed |
| US-4284634-A | HYPOTENSIVE VASODILATORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| EP-0028833-A2 | Imidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
| US-4260551-A | ALIPHATIC OR AROMATIC ESTERS, ANTIULCER AGENTS | SANKYO COMPANY LIMITED (JP) | 1981-04-07 | — | — | US | disclosed |
| JP-S5634664-A | NOVEL COMPOUND HAVING CHELATE FORMING GROUP AND CARBOXYLIC ACID IN MOLECULE | NIPPON MEJIFUIJITSUKUSU KK | 1981-04-06 | — | — | JP | disclosed |
| EP-0024464-A1 | 2-Oxopropionaldehyde bis(thiosemicarbazone)derivatives and their production and use | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1981-03-11 | — | — | EP | disclosed |
| US-4192953-A | TREATMENT OF PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1980-03-11 | — | — | US | disclosed |
| US-4145432-A | 6-ACYLORYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND A METHOD OF EFFECTING VASODILATION THEREWITH | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
| US-4059641-A | ANTIULCER | SANKYO COMPANY LIMITED (JA) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | GAA 1834/4885MGAM 3823/4885SI 1128/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | GAA 1693/4885MGAM 3707/4885SI 3007/4885 |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | GAA 3506/4885MGAM 4083/4885SI 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.